Onkologie. 2014:8(3):112-116

Treating localized stage of Hodgkin's lymphoma

Zdeněk Král
Interní hematologická a onkologická klinika LF MU a FN Brno

The current therapeutic strategy for localized clinical stage of Hodgkin's lymphoma is based on dividing the patients according to the

presence of risk factors into groups with favourable and poor prognosis. The two groups differ in treatment intensity, with patients with a

poor prognosis being administered more chemotherapy and a higher dose of irradiation. In order to reduce late toxicity of radiotherapy,

particularly secondary malignancies, extended-field radiotherapy, EFRT, has been replaced with a technique with a lower target volume, IFRT.

Keywords: Hodgkin's lymphoma, chemotherapy, radiotherapy

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Král Z. Treating localized stage of Hodgkin's lymphoma. Onkologie. 2014;8(3):112-116.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Küppers R. Molecular biology of Hodgkin's lymphoma. Adv Cancer Res. 2002; 84: 277-312. Go to original source... Go to PubMed...
    2. Jaffe ES, Hartus NL, Stein H, et al. Health Organization Classification of Tumors. Patology and Genetics of Tumor sof Haematopoetic and Lymphoid Tissues. IARC Press, Lyon 2001: 351.
    3. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patiens with clinical stages I and II in Hodgkin´s disease. The EORTC Lymhoma Group controlled clinical trials: 1964-1987. Blood, 1989; 73: 47-56. Go to original source...
    4. Engert A, Franclin J, Eich HT, et al. Two cykles of Doxorubicin, Bleomycin, Vinblastin, and Dacarbazin Plus Extended-Field Radiotherapy Is superior to Radiotherapy Alon in Early Favorable Hodgkin´s lymphoma: Final Results of the GHSG HD7 trial. J Clin Oncol, 2007; 25(23): 3495-3502. Go to original source... Go to PubMed...
    5. Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol, 2007; 25(15): 2000-2005. Go to original source... Go to PubMed...
    6. Noordijk EM, Thomas J, Fermé C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol, 2005; 23(Suppl. 1): 6505. Go to original source...
    7. Meyer RM, Gospodarowicz KM, Connors JM, et al. Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.J Clin Oncol, 2005; 2;3: 4634-4642. Go to original source... Go to PubMed...
    8. Duggan D, Petroni G, Johnson J, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin´s disease: report of an intregroup trial. J Clin Oncol, 2003; 21(4): 607-614. Go to original source... Go to PubMed...
    9. Kaplan HS. Hodgkin's disease: biology, treatment, prognosis. Blood, 1981; 57: 813-822. Go to original source...
    10. Feltl D. Potřebujeme radioterapii v léčbě Hodgkinovy choroby? Klin. Onkol., 2003; 16: 184-186.
    11. Jones E, Mauch P. Limited radiation therapy for selected patiens with stage IA and IIA Hodgkin´s disease. Semin Radiation Oncol, 1996; 6: 162-171. Go to original source...
    12. Biti G, Cimino G, Bartoni C, et al. Extendet-field radiotherapy is superior toMOPP chemotherapy of pathologic stage I-IIA Hodgkin´s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol, 1992; 10: 378-382. Go to original source... Go to PubMed...
    13. Kaplan HS. Hodgkin´s disease. Harvard University Press, Cambridge 1980.
    14. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin´s disease. JAMA, 1993; 270: 1949-1955. Go to original source...
    15. Mauch PM, Kalish LA, Marcus KC, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood. 1996; 87(9): 3625-32. Go to original source...
    16. Duhmke E, Franclin J, Preundschuh M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatmnet in favorable early-stage Hodgkin´s disease: long-term results of a randomized trial od radiotherpy alone. J Clin Oncol, 2001; 19: 2905-2914. Go to original source... Go to PubMed...
    17. Horning SJ, Hoppe RT, Hancock SL, et al. Vinblastine, bleomycine and methotrexate: an effective adjuvant in favorable Hodgkin´s disease. J Clin Oncol, 1988; 6: 1822-1831. Go to original source... Go to PubMed...
    18. Radfort JA, Copan RA, Ryder WDJ. Four weeks of neo-adjuvant chemotherapy significantly reduces the progression rate in patiens treated with limited field radiotherapy for clinical stage IA/IIA Hodgkin´s disease. Results of a randomized pilot study. Ann Oncol, 1996; 7: abstr. 66.
    19. Hagenbeek A, Carde P, Noordijk E, et al. Prognostic factor tailored treatment of early stage Hodgkin´s disease. Results from a prospective randomized phase III clinical trial in 762 patients (H7 study). Blood, 1997; 90(Suppl.): abstr. 2603.
    20. Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignaciens following treatment for Hodgkin´s disease. J Clin Oncol, 1986; 4: 830-837. Go to original source... Go to PubMed...
    21. Kulkarni SS, Sastry PS, Saikia TK, et al. Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol, 1997; 20(4): 354-357. Go to original source... Go to PubMed...
    22. Marmor D, Duyck F. Male reproductive potential after MOPP therapy for Hodgkin's disease: a long-term survey. Andrologia, 1995; 27(2): 99-106. Go to original source... Go to PubMed...
    23. Bates NP, Williams MW, Vaughan HG, et al. Efficacy and toxicity of vinblastine, bleomycine, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin´s disease: A British national lymphoma Invstigation pilot study. J Clin Oncol, 1994; 12: 288-296. Go to original source... Go to PubMed...
    24. Gobbi PG, Federico M. What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma? Crit Rev Oncol Hematol. 2012 Apr; 82(1): 18-24. Go to original source... Go to PubMed...
    25. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12; 363(7): 640-652. Go to original source... Go to PubMed...
    26. Raemaekers JM, André MP, Federico M, et al. Omitting Radiotherapy in Early Positron Emission Tomography-Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2014 Apr 20; 32(12): 1188-94. Go to original source... Go to PubMed...
    27. Advari RH, Hoppe RT, Baer D, Mason J, Warnke R, Allen J, Daadi S, Rosenberg SA, Horning SJ. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol. 2013 Apr; 24(4): 1044-1048. Go to original source... Go to PubMed...
    28. Raida L, Papajík T, Indrák K, et al. Chemoterapie BOVAPEC v primární léčbě středně pokročilých stadií Hodgkinova lymfomu. Vnitr Lék, 2007; 53(1): 31-37. Go to PubMed...
    29. Zittun R, Audebert A, Hoerni B, et al. Extended versus involved fields irradiation combined wth MOPP chemotherapy in early clinical stages of Hodgkin´s disease. J Clin Oncol, 1985; 3: 207-214. Go to original source... Go to PubMed...
    30. Santoro A, Bonifante V, Viviani S, et al. Subtotal nodal (STNI) vs. Involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin´s disease. Proc Am Soc Clin Oncol, 1996; 15: Abstr. 1271. Go to PubMed...
    31. Engert A, Schiller P, Josting A, et al. Involved-field radiothyrapy is equally effectiveabd less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patiens with early-stage unfavorable Hodgkin´s lymphoma: results of the HD8 trial of the German Hodgkin´s Lymphoma Study Group. J Clin Oncol, 2003; 21: 3601-3608. Go to original source... Go to PubMed...
    32. Eich HT, Diehl V, Görgen H, Pabst T, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Clin Oncol. 2010 Sep 20; 28(27): 4199-4206. Go to original source... Go to PubMed...
    33. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012 Mar 20; 30(9): 907-913. Go to original source... Go to PubMed...
    34. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin´s disease. N Engl J Med, 1988; 339: 1506-1514. Go to original source... Go to PubMed...
    35. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002 Feb 1; 20(3): 630-637. Go to original source...
    36. Edwards-Bennett SM, Jacks LM, Moskowitz CH, et al. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol. 2010 Mar; 21(3): 574-581. Go to original source... Go to PubMed...
    37. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10; 27(32): 5390-5396. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.